Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +36.65%
#2 Purr Purr +29.32%
#3 OriginTrail OriginTrail +18.52%
#4 DigiByte DigiByte +14.11%
#5 龙虾 (Lobster) 龙虾 (Lobster) +11.90%
#6 Ethena Staked ENA Ethena Staked ENA +11.62%
#7 Collect on Fanable Collect on Fanable +11.50%
#8 UnifAI Network UnifAI Network +10.76%
#9 Siren Siren +9.87%
#10 Wrapped XPL Wrapped XPL +9.81%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Adocia S.A. Adocia S.A.

Adocia S.A.

ADOC
Rang in aandelen #21864
Adocia S.A. is a clinical-stage biotechnology firm that specializes in... Adocia S.A. is a clinical-stage biotechnology firm that specializes in developing enhanced formulations of existing therapeutic proteins and peptides, primarily targeting diabetes and other metabolic disorders. The company leverages its unique BioChaperone technological platform, specifically designed to boost the performance of these therapeutic proteins. Its robust clinical pipeline showcases several advanced insulin formulations, including BioChaperone Lispro U100 and U200, which are ultra-rapid-acting versions of insulin lispro. Other key candidates are BioChaperone Combo, a blend of long-acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, which pairs prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous human glucagon formulation for managing hypoglycemia. M1Pram, a derivative combining insulin glargine and pramlintide, is also under clinical investigation. In its earlier preclinical development phases, Adocia is advancing bi-hormonal products such as BioChaperone AsPram, a combination of rapid insulin aspart and pramlintide, and BioChaperone Glargine Liraglutidea, a fixed-dose pairing of insulin glargine with a GLP-1 receptor analogue. The preclinical portfolio also extends to multihormonal therapies for obesity, featuring BioChaperone GluExe (glucagon and exenatide), PramExe (pramlintide and exenatide), and BioChaperone PramGluExe, a triple combination of pramlintide, glucagon, and exenatide. Adocia has established a strategic partnership with Tonghua Dongbao Pharmaceutical Co., Ltd. to facilitate the development and commercialization of BioChaperone Lispro and BioChaperone Combo in China, as well as selected markets in Asia and the Middle East. The company was founded in 2005 and is headquartered in Lyon, France.
Aandeelprijs
$4.95
Laatst gesynchroniseerd: 2026-08-21
Marktkapitalisatie
$98.96M
Verandering (1 dag)
1.16%
Verandering (1 jaar)
-52.59%
Land
FR
Handel Adocia S.A. (ADOC)

Categorie

Healthcare
Dividendgeschiedenis van Adocia S.A. (ADOC)
Adocia S.A. (aandelsymbool: ADOC) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor Adocia S.A. (ADOC) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH